Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...